Message

From: Wozniak, Chris [wozniak.chris@epa.gov]

Sent: 7/9/2016 3:34:24 PM

To: Dass, Brinda [Brinda.Dass@fda.hhs.gov]; Kough, John [Kough.John@epa.gov]

Subject: RE: Oxitec EA and FONSI

Attachments: Working copy EA 06272016-CAW.docx; Working copy EA 06272016 JLK.docx

DRAFT DELIBERATIVE - DO NOT RELEASE

Brinda,

Attached are our comments on the EA. Neither of us had any comments on the FONSI. We tried to highlight edits / corrections in yellow as there was already multi-color track changes, but we also used track changes of course. I don't think we had anything I would classify as major in terms of issues or need for changes, but in a few cases I think there were some statements which would benefit from clarification (both for us and the public).

The only issue I will raise separately here (and in the comments) is that there seemed to be some emphasis on using spatial separation of OX513A and endangered / threatened species. It may benefit the argument to also mention the lack of or minimal contact with the 42 species in question. I recall when discussing the Stock Island tree snail there was an intimation that a no effect finding was made based on a lack of impact of habitat by the release of mosquitoes. If some stronger statements like this were made for the ESA listed species in general, I think it could go a long way to mitigate issues which otherwise might be made. Lawsuits are always a possibility too, so the more detailed or firm the statements, the better off we all are.

Interesting documents and you all clearly did a great job pulling it together! Thanks for the opportunity to comment.

Chris

From: Dass, Brinda [mailto:Brinda.Dass@fda.hhs.gov]

Sent: Friday, July 08, 2016 2:32 PM

To: Wozniak, Chris <wozniak.chris@epa.gov>; Kough, John <Kough.John@epa.gov>

Subject: RE: Oxitec EA and FONSI

Thanks much Chris.

From: Wozniak, Chris [mailto:wozniak.chris@epa.gov]

Sent: Friday, July 08, 2016 1:58 PM **To:** Dass, Brinda; Kough, John **Subject:** RE: Oxitec EA and FONSI

Hi Brinda,

John and I will talk later today and should be able to get something to you by Monday morning. We both have some comments but I don't think any of mine are particularly significant. More clarifications than anything.

Have a nice weekend!

Chris

From: Dass, Brinda [mailto:Brinda.Dass@fda.hhs.gov]

Sent: Friday, July 08, 2016 1:20 PM

To: Wozniak, Chris <<u>wozniak.chris@epa.gov</u>>; Kough, John <<u>Kough.John@epa.gov</u>>; McAllister, Janet C (CDC)

<jvm6@cdc.gov>; Mutebi, John-Paul (CDC) <grv0@cdc.gov>

Subject: Oxitec EA and FONSI

Dear Chris, John, Janet, and John Paul:

I wanted to check in briefly with you to see if you had any concerns or need for clarification on the Oxitec EA and FONSI we sent to you a few weeks ago. Please feel free to contact me should you need anything while you review these documents.

We look forward to receiving your comments on the 11th. Also, should you require additional time to review please let me know soon as possible.

Many thanks once again.

Best

Brinda